2014 YTD- ETFs Outperformed Managed Funds In Biotech In the past managed life science funds outperformed ETFs but this has reversed in 2014. Fidelity’s flagship Select Biotechnology Portfolio (FBIOX) is up 10% YTD and 41.4% over one year, and 229.6% over 5 years. The fund is concentrated in large cap and mid cap stocks; Gilead […]
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum provided full day coverage offering insights as to how the science driving personalized medicine is reshaping […]
Data To Be Submitted in Q4 For Approval Two Phase III studies with combination drug showed clinically significant improvements in lung function Rayno Life Science Pick and Deja Vu Trade Last April at the same BIO Conference we wrote about Phase II data from Vertex when biopharmaceutical stocks got a‘Turbo Boost “from Vertex.The stock soared 58% […]
Biotech Stocks Weak After 30 Day Rally NASDAQ at 4365 We will be attending the 2014 BIO International Convention this week. We do not expect any major scientific developments but will try to keep you informed on any market moving events. Several hundred global companies will be exhibiting with 28,000 Partnering Meetings planned. Rayno Life […]
Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar and a dovish FED. Silver is also strong.In this week’s Barron’s three […]
Reuters Healthcare